EP Patent

EP3574907B1 — A dual nk-1/nk-3 receptor antagonist for the treatment of sex-hormone-dependent diseases

Assigned to Kandy Therapeutics Ltd · Expires 2023-08-23 · 3y expired

What this patent protects

Patent listed against elinzanetant.

Drugs covered by this patent

elinzanetant (ELINZANETANT)

Patent Metadata

Patent number: EP3574907B1
Jurisdiction: EP
Classification: —
Expires: 2023-08-23
Drug substance claim: No
Drug product claim: No
Assignee: Kandy Therapeutics Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.